vs

Side-by-side financial comparison of REGAL REXNORD CORP (RRX) and Steris (STE). Click either name above to swap in a different company.

REGAL REXNORD CORP is the larger business by last-quarter revenue ($1.5B vs $1.5B, roughly 1.0× Steris). Steris runs the higher net margin — 12.9% vs 4.2%, a 8.7% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs 4.3%). Steris produced more free cash flow last quarter ($199.5M vs $140.6M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs -0.8%).

Regal Rexnord Corporation is a manufacturer of electric motors and power transmission components based in Milwaukee, Wisconsin. The company has manufacturing, sales, and service facilities throughout the United States, Canada, Mexico, Europe, and Asia, with about 29,000 employees.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

RRX vs STE — Head-to-Head

Bigger by revenue
RRX
RRX
1.0× larger
RRX
$1.5B
$1.5B
STE
Growing faster (revenue YoY)
STE
STE
+4.9% gap
STE
9.2%
4.3%
RRX
Higher net margin
STE
STE
8.7% more per $
STE
12.9%
4.2%
RRX
More free cash flow
STE
STE
$58.9M more FCF
STE
$199.5M
$140.6M
RRX
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
-0.8%
RRX

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
RRX
RRX
STE
STE
Revenue
$1.5B
$1.5B
Net Profit
$63.4M
$192.9M
Gross Margin
37.5%
43.8%
Operating Margin
10.8%
18.3%
Net Margin
4.2%
12.9%
Revenue YoY
4.3%
9.2%
Net Profit YoY
53.9%
11.2%
EPS (diluted)
$0.95
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RRX
RRX
STE
STE
Q4 25
$1.5B
$1.5B
Q3 25
$1.5B
$1.5B
Q2 25
$1.5B
$1.4B
Q1 25
$1.4B
$1.5B
Q4 24
$1.5B
$1.4B
Q3 24
$1.5B
$1.3B
Q2 24
$1.5B
$1.3B
Q1 24
$1.5B
$1.1B
Net Profit
RRX
RRX
STE
STE
Q4 25
$63.4M
$192.9M
Q3 25
$79.6M
$191.9M
Q2 25
$79.2M
$177.4M
Q1 25
$57.3M
$145.7M
Q4 24
$41.2M
$173.5M
Q3 24
$72.7M
$150.0M
Q2 24
$62.5M
$145.4M
Q1 24
$19.8M
$-1.4M
Gross Margin
RRX
RRX
STE
STE
Q4 25
37.5%
43.8%
Q3 25
37.0%
44.2%
Q2 25
37.7%
45.1%
Q1 25
37.2%
43.3%
Q4 24
34.9%
44.5%
Q3 24
37.7%
43.6%
Q2 24
36.9%
44.7%
Q1 24
35.7%
40.2%
Operating Margin
RRX
RRX
STE
STE
Q4 25
10.8%
18.3%
Q3 25
11.6%
18.2%
Q2 25
12.2%
17.7%
Q1 25
11.3%
14.6%
Q4 24
8.8%
17.9%
Q3 24
11.8%
16.5%
Q2 24
12.5%
14.5%
Q1 24
8.7%
22.0%
Net Margin
RRX
RRX
STE
STE
Q4 25
4.2%
12.9%
Q3 25
5.3%
13.1%
Q2 25
5.3%
12.8%
Q1 25
4.0%
9.8%
Q4 24
2.8%
12.7%
Q3 24
4.9%
11.3%
Q2 24
4.0%
11.4%
Q1 24
1.3%
-0.1%
EPS (diluted)
RRX
RRX
STE
STE
Q4 25
$0.95
$1.96
Q3 25
$1.20
$1.94
Q2 25
$1.19
$1.79
Q1 25
$0.86
$1.48
Q4 24
$0.61
$1.75
Q3 24
$1.09
$1.51
Q2 24
$0.94
$1.46
Q1 24
$0.30
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RRX
RRX
STE
STE
Cash + ST InvestmentsLiquidity on hand
$521.7M
$423.7M
Total DebtLower is stronger
$4.8B
$1.9B
Stockholders' EquityBook value
$6.8B
$7.2B
Total Assets
$13.9B
$10.6B
Debt / EquityLower = less leverage
0.70×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RRX
RRX
STE
STE
Q4 25
$521.7M
$423.7M
Q3 25
$400.0M
$319.2M
Q2 25
$320.1M
$279.7M
Q1 25
$305.3M
$171.7M
Q4 24
$393.5M
$155.2M
Q3 24
$458.6M
$172.2M
Q2 24
$510.4M
$198.3M
Q1 24
$465.3M
$207.0M
Total Debt
RRX
RRX
STE
STE
Q4 25
$4.8B
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$5.5B
$2.0B
Q3 24
$5.7B
$2.2B
Q2 24
$5.8B
$2.2B
Q1 24
$6.2B
$3.1B
Stockholders' Equity
RRX
RRX
STE
STE
Q4 25
$6.8B
$7.2B
Q3 25
$6.8B
$7.0B
Q2 25
$6.7B
$7.0B
Q1 25
$6.4B
$6.6B
Q4 24
$6.3B
$6.4B
Q3 24
$6.5B
$6.6B
Q2 24
$6.4B
$6.4B
Q1 24
$6.3B
$6.3B
Total Assets
RRX
RRX
STE
STE
Q4 25
$13.9B
$10.6B
Q3 25
$13.9B
$10.4B
Q2 25
$13.9B
$10.4B
Q1 25
$14.0B
$10.1B
Q4 24
$14.0B
$10.0B
Q3 24
$14.6B
$10.2B
Q2 24
$14.6B
$10.1B
Q1 24
$15.1B
$11.1B
Debt / Equity
RRX
RRX
STE
STE
Q4 25
0.70×
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.88×
0.32×
Q3 24
0.87×
0.33×
Q2 24
0.91×
0.35×
Q1 24
1.00×
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RRX
RRX
STE
STE
Operating Cash FlowLast quarter
$167.8M
$298.2M
Free Cash FlowOCF − Capex
$140.6M
$199.5M
FCF MarginFCF / Revenue
9.2%
13.3%
Capex IntensityCapex / Revenue
1.8%
6.6%
Cash ConversionOCF / Net Profit
2.65×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$893.1M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RRX
RRX
STE
STE
Q4 25
$167.8M
$298.2M
Q3 25
$197.5M
$287.8M
Q2 25
$523.2M
$420.0M
Q1 25
$102.3M
$260.8M
Q4 24
$213.2M
$332.8M
Q3 24
$154.8M
$250.7M
Q2 24
$158.3M
$303.7M
Q1 24
$83.1M
$254.8M
Free Cash Flow
RRX
RRX
STE
STE
Q4 25
$140.6M
$199.5M
Q3 25
$174.0M
$201.3M
Q2 25
$493.0M
$326.4M
Q1 25
$85.5M
$189.9M
Q4 24
$183.9M
$243.6M
Q3 24
$125.5M
$148.8M
Q2 24
$125.9M
$195.7M
Q1 24
$64.6M
$163.3M
FCF Margin
RRX
RRX
STE
STE
Q4 25
9.2%
13.3%
Q3 25
11.6%
13.8%
Q2 25
33.0%
23.5%
Q1 25
6.0%
12.8%
Q4 24
12.6%
17.8%
Q3 24
8.5%
11.2%
Q2 24
8.1%
15.3%
Q1 24
4.2%
14.6%
Capex Intensity
RRX
RRX
STE
STE
Q4 25
1.8%
6.6%
Q3 25
1.6%
5.9%
Q2 25
2.0%
6.7%
Q1 25
1.2%
4.8%
Q4 24
2.0%
6.5%
Q3 24
2.0%
7.7%
Q2 24
2.1%
8.4%
Q1 24
1.2%
8.2%
Cash Conversion
RRX
RRX
STE
STE
Q4 25
2.65×
1.55×
Q3 25
2.48×
1.50×
Q2 25
6.61×
2.37×
Q1 25
1.79×
1.79×
Q4 24
5.17×
1.92×
Q3 24
2.13×
1.67×
Q2 24
2.53×
2.09×
Q1 24
4.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RRX
RRX

Other$470.6M31%
Industrial Powertrain Solutions Segment$441.8M29%
Automation And Motion Control Segment$327.7M22%
Power Efficiency Solutions Segment$283.2M19%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons